MDPIT

MDPIT

Multicentre Diltiazem Post Infarction Trial. A clinical trial in which patients age 25–75 were randomised post-acute myocardial infarction to receive either diltiazem, a calcium channel blocker, or a placebo.
 
Conclusion
MDPIT concluded that patients with pulmonary congestion or reduced ejection fraction did less well with diltiazem; those without these risk factors had a marginally significant reduction in cardiac events at one year of follow-up.

MDPIT

Cardiology A clinical trial–Multicenter Diltiazem Post Infarction Trial in which Pts were randomized 3-15 days post MI to receive diltiazem or a placebo. See Diltiazem, Myocardial infarction.